Abstract

The present invention relates to crystalline form of 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H–benzimidazole sodium salt represented by the following structural formula-1a, which is referred to as Rabeprazole sodium.

Formula-1a

The present invention also relates to a process for the preparation of crystalline form of Rabeprazole sodium.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS